- Fovia Ai
CHICAGO, Nov. 28, 2016 /PRNewswire/ -- Volpara Solutions announced the launch of Volpara®Enterprise™ 2.0 software, which helps breast imaging providers deliver high quality, personalized breast screening, here at the 102nd Annual Radiological Society of North America (RSNA) meeting, November 27-December 2, 2016. (RSNA Booth - South Hall #4574).
VolparaEnterprise software, which was commercially launched in 2016, delivers key performance indicators (KPIs) for hundreds of performance and quality metrics, including positioning, compression and equipment utilization. The Microsoft Azure–based solution provides continuous quality assurance and performance monitoring through dynamic, interactive dashboards. Updated with every mammography or tomosynthesis exam, the VolparaEnterprise ConstantQuality™ metrics may help facilities comply with the FDA's new EQUIP inspection program.
Designed to support large or small enterprises, VolparaEnterprise software enables breast imaging providers to provide objective evidence to demonstrate compliance and quality of care. Users can perform rapid quality control checks to optimize the productivity and efficiency of imaging resources, to help reduce costs through the reduction of retakes, and to increase staff effectiveness.
Updates to VolparaEnterprise 2.0 software include additional data and analytics tools to help improve imaging providers' understanding of their performance and provide better understanding of their patient population and referral patterns. A new technologist-specific dashboard enables technologists to monitor their own performance, and the new technologist Quality Quadrant diagram summarizes staff performance on patient positioning and compression to identify training opportunities. A broader use of infographics makes data easier to interpret, and new role-specific "landing pages" summarize performance data for each user.
"VolparaEnterprise has given us the ability to monitor performance and quality every single day. With real-time, objective information, we no longer have to wait for ACR accreditation or for a radiologist to complain about inferior images to learn about quality concerns" said Mindy Shikiar, VP of Operations at Boca Raton Regional Hospital. "We are now beginning to use VolparaEnterprise to reshape the training of our technologists. VolparaEnterprise contains this amazing capability for analyzing patient positioning, which now gives us the ability to objectively identify which technologists are doing well and offer additional training to those who may need it."
VolparaEnterprise software provides Clinical Quality Measures (CQMs1) sought by payers to justify supplemental screening. The objective assessment of volumetric breast density helps reduce time spent by radiologists and technologists on recalls that are not clinically beneficial, such as ultrasound on BI-RADS A/B breasts inadvertently deemed "dense" due to subjective assessment of density. This not only results in better patient care, but preserves proper equipment utilization, staff workflow and productivity.
"In the end, it's all about our patients. We were already proud to offer the Boca Raton community an amazingly well equipped and staffed breast center with dedicated professionals who truly care about our patients' well-being and long-term health. Adding VolparaEnterprise software has enabled us to implement new quality processes that will help ensure that every woman's mammogram is the best that we can offer," said Kathy Schilling, MD, Medical Director of Boca Raton Regional Hospital's Christine E. Lynn Women's Health & Wellness Institute.
Volpara Solutions is showcasing its entire suite of quantitative breast imaging tools, including
VolparaDensity™, at RSNA. The company's technology is currently in use in 35 countries, and more than 9 million women have had their breast density analyzed using VolparaDensity.
About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand (formerly Matakina Technology). Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning and other factors designed to provide critical insight for breast imaging workflow. For more information, visit www.volparasolutions.com.
SOURCE Volpara Solutions